Unveiling the Potential: Can an Anti-Aging Gene Rewind a Heart’s Age?
This Anti-Aging Gene Can Turn Back Your Heart’s Clock by Years! 🕰️✨
The Fountain of Youth in Our Genes:
The ageing heart undergoes a natural decline in function and perfusion that conventional treatments struggle to halt. However, carriers of a healthy mutant gene, often found in centenarians and individuals from ‘blue zone’ regions known for longevity, exhibit a different narrative. These individuals not only live to 100 years or more but also maintain good health and show resistance to cardiovascular complications associated with aging.
Protecting the Heart: A Genetic Gift:
Scientists believe that the identified gene plays a pivotal role in safeguarding the heart against aging-related diseases, such as heart failure. Paolo Madeddu, a professor of experimental cardiovascular medicine, highlights the varying rates of harmful changes in heart function among individuals due to factors like lifestyle choices and genetic inheritance. The study explores how the gene helps to maintain a youthful heart by shielding it from the adverse effects of aging.
The Therapeutic Potential of LAV-BPIFB4:
Carriers of a longevity-associated variant (LAV) of the BPIFB4 gene demonstrate prolonged health spans and reduced cardiovascular complications. Supplementation of LAV-BPIFB4 through gene therapy proves beneficial in improving cardiovascular performance in various models, including limb ischemia, atherosclerosis, and diabetes. The study aims to address the pressing need to delay the heart’s spontaneous aging, especially in the context of ischaemic heart failure.
Cardiac Rejuvenation Unveiled:
Immunohistological studies on hearts from elderly patients with ischemic heart failure reveal a remarkable reduction in vessel coverage by pericytes. However, patients with the homozygous LAV-BPIFB4 genotype show attenuation of this defect. The administration of the anti-aging gene not only halts the decay of heart function in middle-aged mice but also rewinds the heart’s biological clock by more than 10 years in elderly mice, showcasing its potential for cardiac rejuvenation.
Hope for Heart Failure Patients:
The breakthrough presents a promising target for patients with heart failure, offering the possibility of transferring the healthy gene from centenarians to unrelated individuals for heart protection. The study’s first author, Monica Cattaneo, emphasizes the positive impact on pericytes, stating that the addition of the longevity gene leads to cardiac rejuvenation, making the cells more efficient in constructing new blood vessels.
Looking to the Future:
The researchers express optimism about the broader implications of their findings, suggesting a potential new wave of treatments inspired by the genetics of centenarians. While acknowledging that this is early-stage research, Professor James Leiper, associate medical director at the British Heart Foundation, anticipates a revolutionary approach to treating heart failure and preventing its development in the first place.
The results of the study provide hope for reversing the deterioration of heart function in older people by utilizing a healthy gene present in centenarians. As the investigation continues, there is optimism that this genetic finding may result in revolutionary heart failure therapies, moving us closer to understanding the mechanisms underlying aging and improving cardiovascular health.
Quail D.F., Joyce J.A. The microenvironmental landscape of brain tumors. Cancer Cell. 2017;31:326–341. doi: 10.1016/j.ccell.2017.02.009. – DOI – PMC – PubMed
Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., Belanger K., Brandes A.A., Marosi C., Bogdahn U. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005;352:987–996. doi: 10.1056/NEJMoa043330. – DOI – PubMed
Lawless C, Wang C, Jurk D, Merz A, Zglinicki T, Passos JF. Quantitative assessment of markers for cell senescence. Exp Gerontol 2010;45:772–778.
Terman A, Brunk UT. Oxidative stress, accumulation of biological ‘garbage’, and ageing. Antioxid Redox Signal 2006;8:197–204.
Simpson RU. Selective knockout of the vitamin d receptor in the heart results in cardiac hypertrophy: is the heart a drugable target for vitamin D receptor agonists? Circulation 2011;124:1808–1810.
Durut N, Saez-Vasquez J. Nucleolin: dual roles in rDNA chromatin transcription. Gene 2015;556:7–12.
Huang Y, Shi H, Zhou H, Song X, Yuan S, Luo Y. The angiogenic function of nucleolin is mediated by vascular endothelial growth factor and nonmuscle myosin. Blood 2006;107:3564–3571.
Malovannaya A, Lanz RB, Jung SY, Bulynko Y, Le NT, Chan DW, Ding C, Shi Y, Yucer N, Krenciute G, Kim BJ, Li C, Chen R, Li W, Wang Y, O’Malley BW, Qin J. Analysis of the human endogenous coregulator complexome. Cell 2011;145:787–799.
Charoenpanichkit C, Hundley WG. The 20 year evolution of dobutamine stress cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2010;12:59.
Avolio E, Katare R, Thomas AC, Caporali A, Schwenke D, Carrabba M, Meloni M, Caputo M, Madeddu P. Cardiac pericyte reprogramming by MEK inhibition promotes arteriologenesis and angiogenesis of the ischemic heart. J Clin Invest 2022;132:e152308. doi:10.1172/JCI152308.